ABBOTT INDIA | UNICHEM LAB | ABBOTT INDIA/ UNICHEM LAB |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 47.1 | -41.4 | - | View Chart |
P/BV | x | 15.4 | 1.0 | 1,511.4% | View Chart |
Dividend Yield | % | 0.4 | 1.4 | 32.9% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
UNICHEM LAB Mar-19 |
ABBOTT INDIA/ UNICHEM LAB |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 292 | 3,025.4% | |
Low | Rs | 5,458 | 182 | 2,998.6% | |
Sales per share (Unadj.) | Rs | 1,731.1 | 167.7 | 1,032.5% | |
Earnings per share (Unadj.) | Rs | 211.9 | -3.6 | -5,836.9% | |
Cash flow per share (Unadj.) | Rs | 219.9 | 5.9 | 3,700.7% | |
Dividends per share (Unadj.) | Rs | 65.00 | 4.00 | 1,625.0% | |
Dividend yield (eoy) | % | 0.9 | 1.7 | 53.9% | |
Book value per share (Unadj.) | Rs | 945.2 | 372.3 | 253.9% | |
Shares outstanding (eoy) | m | 21.25 | 70.38 | 30.2% | |
Bonus/Rights/Conversions | - | ESOP | - | ||
Price / Sales ratio | x | 4.1 | 1.4 | 292.0% | |
Avg P/E ratio | x | 33.7 | -65.3 | -51.7% | |
P/CF ratio (eoy) | x | 32.5 | 39.9 | 81.5% | |
Price / Book Value ratio | x | 7.6 | 0.6 | 1,187.4% | |
Dividend payout | % | 30.7 | -110.2 | -27.8% | |
Avg Mkt Cap | Rs m | 151,848 | 16,680 | 910.4% | |
No. of employees | `000 | 3.5 | 2.6 | 133.9% | |
Total wages/salary | Rs m | 4,356 | 2,393 | 182.0% | |
Avg. sales/employee | Rs Th | 10,555.5 | 4,535.2 | 232.7% | |
Avg. wages/employee | Rs Th | 1,249.9 | 919.8 | 135.9% | |
Avg. net profit/employee | Rs Th | 1,292.2 | -98.2 | -1,315.8% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 11,801 | 311.7% | |
Other income | Rs m | 1,133 | 984 | 115.1% | |
Total revenues | Rs m | 37,919 | 12,785 | 296.6% | |
Gross profit | Rs m | 6,047 | -835 | -724.3% | |
Depreciation | Rs m | 169 | 674 | 25.1% | |
Interest | Rs m | 23 | 75 | 29.9% | |
Profit before tax | Rs m | 6,989 | -600 | -1,165.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 1 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,485 | -343 | -723.6% | |
Profit after tax | Rs m | 4,503 | -256 | -1,762.3% | |
Gross profit margin | % | 16.4 | -7.1 | -232.4% | |
Effective tax rate | % | 35.6 | 57.3 | 62.1% | |
Net profit margin | % | 12.2 | -2.2 | -565.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 20,384 | 135.4% | |
Current liabilities | Rs m | 8,569 | 5,029 | 170.4% | |
Net working cap to sales | % | 51.8 | 130.1 | 39.8% | |
Current ratio | x | 3.2 | 4.1 | 79.5% | |
Inventory Days | Days | 60 | 105 | 57.5% | |
Debtors Days | Days | 27 | 135 | 20.3% | |
Net fixed assets | Rs m | 1,057 | 9,023 | 11.7% | |
Share capital | Rs m | 213 | 141 | 150.9% | |
"Free" reserves | Rs m | 19,873 | 26,058 | 76.3% | |
Net worth | Rs m | 20,086 | 26,199 | 76.7% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 29,409 | 31,496 | 93.4% | |
Interest coverage | x | 311.6 | -7.0 | -4,467.6% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.3 | 0.4 | 333.9% | |
Return on assets | % | 15.4 | -0.6 | -2,687.8% | |
Return on equity | % | 22.4 | -1.0 | -2,298.7% | |
Return on capital | % | 34.9 | -2.0 | -1,745.9% | |
Exports to sales | % | 0 | 69.4 | 0.0% | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | 8,188 | 0.0% | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 369 | 8,188 | 4.5% | |
Fx outflow | Rs m | 4,918 | 596 | 825.2% | |
Net fx | Rs m | -4,549 | 7,592 | -59.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | -3,278 | -152.3% | |
From Investments | Rs m | -2,570 | -2,860 | 89.9% | |
From Financial Activity | Rs m | -1,428 | -24 | 5,900.8% | |
Net Cashflow | Rs m | 993 | -4,690 | -21.2% |
Indian Promoters | % | 0.0 | 50.1 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.9 | 15.1 | 52.3% | |
FIIs | % | 0.1 | 3.0 | 3.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.1 | 31.7 | 53.9% | |
Shareholders | 18,270 | 20,176 | 90.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ABBOTT INDIA With: TORRENT PHARMA NATCO PHARMA AJANTA PHARMA PIRAMAL ENTERPRISES ALKEM LABORATORIES
Compare ABBOTT INDIA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More